Dr. Lal Path Labs Ltd.

rs 40

diagnostics India’s Leading & Trusted Diagnostics Company 131 Mn patients serviced in last 5 years 40 NABL accredited Labs; 2 CAP accredited Labs 6,607 Patient Service Centers (PSC’s) 5,012 Patholo

10.5%

hology & Radiology tests; Comprehensive Test menu 298 Labs; Geographically spread-out network 10.5% FY25 Revenue Growth 48% ROCE Excl. Cash & Investments 240% Dividend for FY24-25 Credit Ra

48%

mprehensive Test menu 298 Labs; Geographically spread-out network 10.5% FY25 Revenue Growth 48% ROCE Excl. Cash & Investments 240% Dividend for FY24-25 Credit Rating# : AA Stable 4 As

240%

ographically spread-out network 10.5% FY25 Revenue Growth 48% ROCE Excl. Cash & Investments 240% Dividend for FY24-25 Credit Rating# : AA Stable 4 As on March 31, 2025 *Largest on the bas

Rs. 670 crore

ce Overview Revenue EBITDA PAT Patients Samples SwasthFitTM Contribution Q1 FY26 Q1 FY25 Rs. 670 crore Rs. 602 crore 11.3% Rs. 192 crore Rs. 170 crore 13.1% Rs. 134 crore Rs. 108 crore 24.3% 7.

Rs. 602 crore

venue EBITDA PAT Patients Samples SwasthFitTM Contribution Q1 FY26 Q1 FY25 Rs. 670 crore Rs. 602 crore 11.3% Rs. 192 crore Rs. 170 crore 13.1% Rs. 134 crore Rs. 108 crore 24.3% 7.6 MN 7.2 MN 5

11.3%

PAT Patients Samples SwasthFitTM Contribution Q1 FY26 Q1 FY25 Rs. 670 crore Rs. 602 crore 11.3% Rs. 192 crore Rs. 170 crore 13.1% Rs. 134 crore Rs. 108 crore 24.3% 7.6 MN 7.2 MN 5.3% 23

Rs. 192 crore

atients Samples SwasthFitTM Contribution Q1 FY26 Q1 FY25 Rs. 670 crore Rs. 602 crore 11.3% Rs. 192 crore Rs. 170 crore 13.1% Rs. 134 crore Rs. 108 crore 24.3% 7.6 MN 7.2 MN 5.3% 23.4 MN 21.1 MN

Rs. 170 crore

s SwasthFitTM Contribution Q1 FY26 Q1 FY25 Rs. 670 crore Rs. 602 crore 11.3% Rs. 192 crore Rs. 170 crore 13.1% Rs. 134 crore Rs. 108 crore 24.3% 7.6 MN 7.2 MN 5.3% 23.4 MN 21.1 MN 10.7% 27% 25

13.1%

Contribution Q1 FY26 Q1 FY25 Rs. 670 crore Rs. 602 crore 11.3% Rs. 192 crore Rs. 170 crore 13.1% Rs. 134 crore Rs. 108 crore 24.3% 7.6 MN 7.2 MN 5.3% 23.4 MN 21.1 MN 10.7% 27% 25% 2%

Rs. 134 crore

bution Q1 FY26 Q1 FY25 Rs. 670 crore Rs. 602 crore 11.3% Rs. 192 crore Rs. 170 crore 13.1% Rs. 134 crore Rs. 108 crore 24.3% 7.6 MN 7.2 MN 5.3% 23.4 MN 21.1 MN 10.7% 27% 25% 2% 5 Financials

Rs. 108 crore

Q1 FY25 Rs. 670 crore Rs. 602 crore 11.3% Rs. 192 crore Rs. 170 crore 13.1% Rs. 134 crore Rs. 108 crore 24.3% 7.6 MN 7.2 MN 5.3% 23.4 MN 21.1 MN 10.7% 27% 25% 2% 5 Financials Particulars (Rs

“Our outlook is shaped by a relentless focus on volume-led growth through market expansion, focus on operational excellence via digital transformation and sustaining our brand leadership through quality and accessibility.” “We have commenced FY26 on a strong note, with steady growth in volumes and healthy improvement in business mix, yielding a robust financial outcome.”

“In FY25 & FY24, DLPL collected and processed approximately 86 million samples and 78 million samples from 28.8 million and 27.6 million patients, respectively.”

Chief Executive Officer said

1

For further information please contact

1

Chief Executive Officer said

Commenting on the performance, Mr. Ved Prakash Goel, Group CFO & CEO – International Business said: “Our first-quarter performance reinforces the strength of our business model and disciplined execution. We are expanding access to high-quality diagnostics through a calibrated network rollout, deeper reach increased presence in underpenetrated regions. The diagnostics landscape continues to evolve, and we are positioning ourselves to lead not just in scale, but also in trust and reliability. in core metro markets and We are steadily broadening our capabilities across advanced diagnostics, including genomics, auto-immunity and other high- complexity testing, to ensure that our offerings meet both emerging and unmet needs in healthcare. Our SwasthFit program continues to gain momentum, helping us deliver diagnostic solutions that support clinical decision-making and aid prevention. We continue to invest in Technology, which remains central to how we operate and grow. Our outlook is shaped

For further information please contact

Ved Prakash Goel Dr. Lal PathLabs Limited Tel: +91 124 301 6500 Fax: +91 124 423 4468 E-mail: ved.goel@lalpathlabs.com Siddharth Rangnekar / Nishid Solanki CDR India Tel: +91 22 66451209 / 1221 Fax: +91 22 66451213 Email: siddharth@cdr-india.com / nishid@cdr-india.com 38